José María García‐Acuña

ORCID: 0000-0003-0119-1710
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myocardial Infarction Research
  • Cardiac Imaging and Diagnostics
  • Cardiovascular Function and Risk Factors
  • Atrial Fibrillation Management and Outcomes
  • Heart Failure Treatment and Management
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Blood Pressure and Hypertension Studies
  • Coronary Interventions and Diagnostics
  • Cardiac, Anesthesia and Surgical Outcomes
  • Cardiac Structural Anomalies and Repair
  • Chronic Kidney Disease and Diabetes
  • Venous Thromboembolism Diagnosis and Management
  • Cardiac pacing and defibrillation studies
  • Cardiac Arrhythmias and Treatments
  • Acute Kidney Injury Research
  • Cardiac Arrest and Resuscitation
  • Cardiac Valve Diseases and Treatments
  • Mechanical Circulatory Support Devices
  • Cardiac Health and Mental Health
  • Takotsubo Cardiomyopathy and Associated Phenomena
  • Cardiac electrophysiology and arrhythmias
  • Acute Ischemic Stroke Management
  • Lipoproteins and Cardiovascular Health
  • Health Systems, Economic Evaluations, Quality of Life
  • Hormonal Regulation and Hypertension

Complejo Hospitalario Universitario de Santiago
2015-2024

Centro de Investigación en Red en Enfermedades Cardiovasculares
2017-2024

Centro de Investigación Biomédica en Red
2017-2024

Universidade de Santiago de Compostela
2013-2023

Lankenau Institute for Medical Research
2023

Medical Research Network
2021-2022

Complexo Hospitalario Universitario A Coruña
1998-2021

Instituto de Investigación Sanitaria de Santiago
2006-2021

Centre for Biomedical Network Research on Rare Diseases
2021

Servicio Gallego de Salud
2019-2021

Manuel Almendro‐Delia Iván J. Núñez‐Gil Manuel Lobo Mireia Andrés Óscar Vedia and 84 more Alessandro Sionís Ana Martín‐Garcia Maria Aguilera Eduardo Pereyra Irene Martín de Miguel José Antonio Linares Vicente Miguel Corbí‐Pascual Xavier Bosch Óscar Fabregat Andrés Alejandro Sánchez Grande Flecha Alberto Pérez‐Castellanos Javier López País Manuel de Mora Martín Juan Manuel Escudier-Villa Roberto Martín‐Asenjo Marta Guillén Marzo Ferran Rueda Álvaro Aceña José María García‐Acuña Juan C. Garcı́a-Rubira Jaime Figueras José A. Barrabés Mireia Andrés Iván J. Núñez‐Gil H.D. Mejía O Vedia Gisela Feltes Fernando Worner Ramón Bascompte Claret E Pereyra Javier Jiménez‐Candil M.J. García Sánchez A.C. Martín García Ana Martín‐Garcia Vicente Bodı́ C. Bonanad Teresa Bastante Maria Aguilera Jorge Palazuelos D. Carmona J Lopez Pais Joaquín Alonso M Almendro Delia Martín Lobo Sergio Rodríguez de Leiras Juan C. Garcı́a-Rubira Miguel Corbí‐Pascual Juan Gabriel Córdoba Soriano Manuel de Mora Martín Beatriz Pérez R. Martín Asensio F Rueda Sobella I. Santos Pardo M C Nieto Juan Manuel Escudier-Villa Óscar Fabregat Andrés Francisco Ridocci-Soriano M.N. Parias Ángel Hans Paul Gaebelt Álvaro Aceña R. Martin Reyes C. Bergua P. Sanz Puértolas Ignacio Lucotti Rafael Vidal-Pérez Alessandro Sionís Albert Duran‐Cambra J. Tómas Ortiz Xavier Bosch Marta Guillén Marzo R.A. Bardají José María García‐Acuña Alejandro Sánchez Grande Flecha M. J. García González G. Redondo Alberto Pérez Castellanos Jesús Piqueras‐Flores Loles Herrero José Antonio Linares Vicente José R. Ruiz Arroyo Juan Luis Garcı́a José Antonio Giner Manuel Martínez‐Sellés Irene Martín de Miguel

10.1016/j.jchf.2018.05.015 article EN publisher-specific-oa JACC Heart Failure 2018-10-10

Background: The prevalence and outcome of patients with cancer that experience acute coronary syndrome (ACS) have to be determined. Methods results: BleeMACS project is a multicentre observational registry enrolling undergoing percutaneous intervention worldwide in 15 hospitals. primary endpoint was composite event death re-infarction after one year follow-up. Bleedings were the secondary endpoint. 15,401 enrolled, 926 (6.4%) group 14,475 (93.6%) without cancer. Patients older (70.8±10.3 vs....

10.1177/2048872617706501 article EN European Heart Journal Acute Cardiovascular Care 2017-06-08

Background Takotsubo syndrome ( TTS ) is an acute reversible heart condition initially believed to represent a benign pathology attributable its self‐limiting clinical course; however, little known about prognosis based on different triggers. This study compared short‐ and long‐term outcomes between triggers, focusing various physical triggering events. Methods Results We analyzed patients with definitive diagnosis recruited for the Spanish National Registry (RETAKO [Registry Syndrome])....

10.1161/jaha.119.013701 article EN cc-by-nc-nd Journal of the American Heart Association 2019-12-13

Haemorrhagic complications are strongly linked with adverse outcomes in acute coronary syndrome (ACS) patients. Various risk scores (RS) available to predict bleeding these We compared the performance of three contemporary RS ACS.We studied 4500 consecutive patients ACS. calculated ACTION, CRUSADE, and Mehran et al. (2010) RS, evaluated their for predicting own major events TIMI serious (major or minor) episodes, either non-ST-elevation ACS (NSTEACS) ST-elevation myocardial infarction...

10.1177/2048872612453924 article EN European Heart Journal Acute Cardiovascular Care 2012-07-09

Abstract Background Remnant cholesterol has been identified as one of leading lipid values associated with the incidence coronary heart disease. There is scarce evidence on its distribution and prognostic value in acute syndrome (ACS) patients. Methods results We included all consecutive patients admitted for ACS two different centres. was calculated by equation: total minus LDL HDL cholesterol, ≥30 were considered high. Among 7479 patients, median remnant level 28 mg/dL (21–39), 3429...

10.1093/eurjpc/zwac286 article EN European Journal of Preventive Cardiology 2022-12-23

Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value fluorescent AGEs and its soluble receptor (sRAGE) context acute coronary syndrome (ACS), both in-hospital phase follow-up period.A prospective clinical performed patients with debut's ACS. endpoints were development cardiac events (cardiac deaths, re-infarction new-onset heart failure) during period (366 days, inter-quartile range:...

10.1371/journal.pone.0074302 article EN cc-by PLoS ONE 2013-09-13

No evidence-based therapy has yet been established for Takotsubo syndrome (TTS). Given the putative harmful effects of catecholamines in patients with TTS, beta-blockers may potentially decrease intensity detrimental cardiac those patients. The purpose this study was to assess impact beta-blocker on long-term mortality and TTS recurrence. cohort used national Spanish Registry TakoTsubo Syndrome (RETAKO). A total 970 post-discharge survivors, without pheochromocytoma, left ventricular outflow...

10.1016/j.repc.2022.02.010 article EN cc-by-nc-nd Revista Portuguesa de Cardiologia 2023-01-09

The benefit of complete or incomplete percutaneous coronary intervention (PCI) in patients with myocardial infarction and multivessel disease remains debated. aim our study was to compare a vs. "culprit only" revascularisation strategy distinguishing the different clinical subsets (STEMI NSTEMI) provide one-year outcome from "real-life" BleeMACS (Bleeding complications Multicenter registry discharged diagnosis Acute Coronary Syndrome) registry.We conducted multicentre including all included...

10.4244/eij-d-16-00350 article EN EuroIntervention 2017-07-01
Coming Soon ...